title: Addition of cladribine to induction/consolidation regimen does not impair peripheral blood stem cell mobilization and bone marrow harvest for autotransplantation in acute myeloid leukemia patients.
abstract: BACKGROUND
  The previous study by the Polish Adult Leukemia Group has demonstrated that addition of cladribine to standard DNR+AraC induction potentiates the antileukemic activity. The goal of this study was to compare the efficacy of bone marrow or peripheral blood hematopoietic cell collection in patients who obtained remission after daunorubicine plus cytarabine induction with cladribine (DAC-7) or without addition of cladribine (DA-7) in preparation for autotransplantation.
  
  
  METHODS
  Sixty-six patients aged 41 years (range, 17-58 years) were included in this study: 33 cases in the DAC-7 and 33 in the DA-7 arm. Hematopoietic cells were collected from the bone marrow (ABMT, n = 29) or from the peripheral blood (ABCT, n = 37) using cytopheresis after administration of AraC (2 x 2 g/m2) on days 1, 3, 5 and subsequent G-CSF (10 microg/kg) from day 7 as mobilization therapy.
  
  
  RESULTS
  The numbers of harvested CD34+ cells were similar in the DAC-7 and DA-7 pretreated patients both after harvesting from peripheral blood (2.55 x 10(6)/kg vs 2.5 x 10(6)/kg) and from bone marrow (1.62 x 10(6)/kg vs 1.55 x 10(6)/kg), respectively. The proportion of patients with sufficient material for autologous bone marrow transplantation was higher in the DAC-7 compared with the DA-7 arm. All patients engrafted; hematopoietic recovery was similar in both subgroups.
  
  
  CONCLUSIONS
  Addition of cladribine to a standard DA induction does not impair the harvesting of hematopoietic cells and their engraftment after autotransplantation.
authors.affiliation: Polish Adult Leukemia Group (PALG), University Department of Haematology and BMT, Silesian Medical Academy, Katowice, Poland. holow@mail.slam.katowice.pl
authors.forename: J
authors.initials: J
authors.lastname: Holowiecki
authors.forename: S
authors.initials: S
authors.lastname: Grosicki
authors.forename: M
authors.initials: M
authors.lastname: Sadus-Wojciechowska
authors.forename: L
authors.initials: L
authors.lastname: Kachel
authors.forename: A
authors.initials: A
authors.lastname: Hellmann
authors.forename: A
authors.initials: A
authors.lastname: Mital
authors.forename: A B
authors.initials: AB
authors.lastname: Skotnicki
authors.forename: B
authors.initials: B
authors.lastname: Piatkowska-Jakubas
authors.forename: W W
authors.initials: WW
authors.lastname: Jedrzejczak
authors.forename: M
authors.initials: M
authors.lastname: Paluszewska
authors.forename: M
authors.initials: M
authors.lastname: Wach
authors.forename: B
authors.initials: B
authors.lastname: Marianska
authors.forename: A
authors.initials: A
authors.lastname: Wrzesien-Kus
authors.forename: M
authors.initials: M
authors.lastname: Krawczyk-Kulis
authors.forename: J
authors.initials: J
authors.lastname: Wojnar
mesh_terms: D000293:Adolescent; D000328:Adult; D018952:Antigens, CD34 / Q000097:blood; D016026:Bone Marrow Transplantation; D017338:Cladribine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D019650:Hematopoietic Stem Cell Mobilization; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D008875:Middle Aged; D020858:Tissue and Organ Harvesting / Q000379:methods; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous
chemical_list: D018952:Antigens, CD34; D007166:Immunosuppressive Agents; D017338:Cladribine